These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35992099)

  • 1. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
    Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
    Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
    Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
    Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
    Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
    Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
    Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
    Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
    Gatto F; Arvigo M; Ferone D
    J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
    Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
    J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
    Peverelli E; Giardino E; Treppiedi D; Vitali E; Cambiaghi V; Locatelli M; Lasio GB; Spada A; Lania AG; Mantovani G
    Endocrinology; 2014 Aug; 155(8):2932-41. PubMed ID: 24828612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.
    Vitali E; Cambiaghi V; Zerbi A; Carnaghi C; Colombo P; Peverelli E; Spada A; Mantovani G; Lania AG
    Endocr Relat Cancer; 2016 Mar; 23(3):181-90. PubMed ID: 26733502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
    Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST
    Amarù J; Barbieri F; Arvigo M; Solari A; Bajetto A; Nista F; Campana C; Gaggero G; Prior A; Criminelli Rossi D; Zona G; Ferone D; Florio T; Gatto F
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
    Gatto F; Arvigo M; Amarù J; Campana C; Cocchiara F; Graziani G; Bruzzone E; Giusti M; Boschetti M; Ferone D
    Pituitary; 2019 Feb; 22(1):89-99. PubMed ID: 30483918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
    Siehler S; Seuwen K; Hoyer D
    Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
    Ferrante E; Pellegrini C; Bondioni S; Peverelli E; Locatelli M; Gelmini P; Luciani P; Peri A; Mantovani G; Bosari S; Beck-Peccoz P; Spada A; Lania A
    Endocr Relat Cancer; 2006 Sep; 13(3):955-62. PubMed ID: 16954443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma
    Graillon T; Romano D; Defilles C; Lisbonis C; Saveanu A; Figarella-Branger D; Roche PH; Fuentes S; Chinot O; Dufour H; Barlier A
    Oncotarget; 2017 Aug; 8(33):55361-55373. PubMed ID: 28903425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.